TP53 and neoplasm: Current studies have been identified recurrent genetic abnormalities, notably including functional inactivation of tumor suppressor genes (e.g., BRCA1/2 and TP53 mutations) 7, 8, and oncogenic amplification events (e.g., RAD21 gene amplification) 9, which collectively drive tumor progression.